Radiotherapy plus CAR-T cell therapy to date: A note for cautions optimism?

Area of Science:

• Oncology
• Immunotherapy
• Radiation Oncology

Background:

• Radiotherapy (RT) efficacy is limited by radioresistance, influenced by tumor microenvironment (TME) factors like hypoxia, immune cell radiosensitivity, and cancer stem cells (CSCs).
• Chimeric antigen receptor (CAR)-T cell therapy offers potential for solid tumor treatment, especially when targeting CSCs.
• Solid tumors often present an immunosuppressive TME, hindering CAR-T cell therapy effectiveness.

Purpose of the Study:

• To review radioresistance mechanisms and CAR-T cell therapy barriers in solid tumors within the TME.
• To explore the potential of combining RT with CAR-T cell therapy to overcome treatment limitations.
• To discuss the challenges and future directions of this combined therapeutic strategy.

Main Methods:

• Literature review focusing on radioresistance mechanisms in the TME.
• Analysis of CAR-T cell therapy advancements and limitations in solid tumors.
• Evaluation of preclinical and clinical evidence supporting RT and CAR-T cell combination therapy.

Main Results:

• RT can overcome immunosuppressive TME features, potentially sensitizing tumors to CAR-T cell therapy.
• Targeting CSCs with CAR-T cells may enhance the elimination of radioresistant tumor cells.
• The combination strategy presents a promising approach to address limitations of both individual therapies.

Conclusions:

• Combining RT with CAR-T cell therapy is a promising strategy to combat radioresistance and immunosuppression in solid tumors.
• Addressing TME barriers and CSCs is crucial for successful CAR-T cell therapy in conjunction with RT.
• Further research is needed to optimize this therapeutic partnership and overcome associated challenges.